Actions

Monoclonal B lymphocytosis: Difference between revisions

From haematologyetc.co.uk

No edit summary
No edit summary
Line 15: Line 15:
<font color="navy">'''1. Flow cytometry defined features:'''</font>
<font color="navy">'''1. Flow cytometry defined features:'''</font>


*Evidence that there is a monoclonal population of B lymphocytes (this can be based on their light chain retriction or abnormal phenotype features)
*Evidence that there is a '''monoclonal population of B lymphocytes''' (this can be based on their light chain retriction or abnormal phenotype features)


*A profile of flow cytometric profile that suggests either CLL or other LPD
*A profile of by '''flow cytometry that suggests either CLL or other LPD''', based on the abnormal gated population that may be a minority of cells


*A count of abnormal cells that is <1x10<sup>9</sup> for the abnormal poulation (ideally inferred from flow cytometry and absolute lymphocyte count
*A '''count of abnormal cells that is <1x10<sup>9</sup> for the abnormal poulation''' (usually calculated from the gated abnormal poulation and the absolute lymphocyte count




'''2. Clinical evidence that there is no significant tissue disease:


<font color="navy">'''2. '''Additional clinical evidence''' that there is no significant tissue disease:'''</font>


*No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells
*No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells

Revision as of 16:01, 18 June 2023



Monoclonal B-lymphocytosis (MBL) as a distinct entity recognised in the WHO Classification and used to denote the presence of abnormal conal B-cells that do not meet the diagnostic criteria for CLL or other LPD based. It is an important distinction since affected individaual are not regarded as having a lymphoproliferative disorder, although they may experience some symptoms, and the disease may progress.

The diagnosis is suggested from flow cytometry of blood, but always requires clinical confirmation - it is important that reports reflect the need for additional clinical conformation.



Diagnosis is made from blood assessment by flow cytometry and is based on the following criteria:


1. Flow cytometry defined features:

  • Evidence that there is a monoclonal population of B lymphocytes (this can be based on their light chain retriction or abnormal phenotype features)
  • A profile of by flow cytometry that suggests either CLL or other LPD, based on the abnormal gated population that may be a minority of cells
  • A count of abnormal cells that is <1x109 for the abnormal poulation (usually calculated from the gated abnormal poulation and the absolute lymphocyte count


2. Additional clinical evidence that there is no significant tissue disease:

  • No evidence of lymph node enlargment or other significant tissue involvements by the abnormal cells
  • No other features suggesting an active B-lymphoproliferative disease or lymphoma